Evidence map›Paper›PMID 29378790›Full record

Observational studyJournal of neurology, neurosurgery, and psychiatry2018

Features of

Naveed Malek, Rimona S Weil, Catherine Bresner, Michael A Lawton, Katherine A Grosset, Manuela Tan, Nin Bajaj, Roger A Barker, David J Burn, Thomas Foltynie and 7 more

2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Journal of neurology, neurosurgery, and psychiatry, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 93 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
93citing papers in PubMed, 4 pooled it
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02881099 completednot on this map

Parkinson's Repository of Biosamples and Network Datasets (Tracking Parkinson's)

TypeobservationalSponsorSouth Glasgow University Hospitals NHS TrustRan2011 to 2022Enrolled2,614ConditionsParkinson's Disease
NCT06451419 enrolling by invitationnot on this mapstarted 2024, after this paper: background citation

Prospective and Controlled Glucocerebrosidase-related Parkinson's Disease Evaluation of Non Motor Symptoms (PROGENS-PD)

TypeobservationalSponsorJuan Pablo Romero. MD, PhDRan2024 to 2026Enrolled40ConditionsParkinson DiseaseArmsTests on non motor symptoms
3 · Its place in the literature

Who cites it

93 citing papers in PubMed, 4 syntheses or guidelines pooled it, 139 citations in OpenAlex.

  1. Pooled it
  2. Role of Lysosomal Gene Variants in Modulating GBA-Associated Parkinson's Disease Risk.Movement disorders : official journal of the Movement Disorder Society · 2022
    Pooled it
  3. Pooled it
  4. Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2021
    Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Pathology and genetics in a global cohort of Parkinsonian Disorders.medRxiv : the preprint server for health sciences · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Exploring GBA1 gene in Parkinson's disease: Prevalence and variant spectrum from Asia minor.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025
    Article
  14. Article
  15. Article
  16. Article
  17. Interpretable Machine Learning for Cross-Cohort Prediction of Motor Fluctuations in Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  18. Article
  19. Article
  20. Review

33 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 8 institutions in 2 countries.

Naveed MalekDepartment of Neurology, Ipswich Hospital NHS Trust, Ipswich, UK.
Rimona S WeilDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, UK.ORCID 0000-0002-5092-6325
Catherine BresnerInstitute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
Michael A LawtonSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Katherine A GrossetDepartment of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, Scotland.
Manuela TanDepartment of Clinical Neuroscience, UCL Institute of Neurology, London, UK.
Nin BajajDepartment of Neurology, Queen's Medical Centre, Nottingham, UK.
Roger A BarkerDepartment of Clinical Neurosciences, John van Geest Centre for Brain Repair, Cambridge, UK.
David J BurnFaculty of Medical Sciences, University of Newcastle, Newcastle upon Tyne, UK.
Thomas FoltynieSobell Department of Motor Neuroscience, UCL Institute of Neurology, London, UK.
John HardyDepartment of Molecular Neuroscience, Reta Lila Weston Laboratories, UCL Institute of Neurology, London, UK.
Nicholas W WoodDepartment of Molecular Neuroscience, UCL Institute of Neurology, London, UK.
Yoav Ben-ShlomoSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Nigel W WilliamsInstitute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK.
Donald G GrossetDepartment of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, Scotland.
Huw R MorrisDepartment of Clinical Neuroscience, UCL Institute of Neurology, London, UK.
PRoBaND clinical consortium
University College London · GBCardiff University · GBInstitute of Neurological Sciences · ITUniversity of Bristol · GBIpswich Hospital · GBNewcastle University · GBQueen's Medical Centre · GBSobell House · GB

Funding

Department of HealthMedical Research Council G0700943Medical Research Council G1100643Medical Research Council MC_G1000735Medical Research Council MR/L010305/1Medical Research Council MR/L501554/1Parkinson's UK H-1703Parkinson's UK J-1101Wellcome Trust 205167/Z/16/Z
6 · The paper itself

Abstract

objectivesTo examine the influence of the glucocerebrosidase (

methodsWe prospectively recruited patients with PD in the

resultsWe studied 1893 patients with PD: 48 (2.5%) were heterozygous carriers for known Gaucher's disease (GD) causing pathogenic mutations; 117 (6.2%) had non-synonymous variants, previously associated with PD, and 28 (1.5%) patients carried variants of unknown significance in the

conclusionsOur study confirms the influence of CLINICAL

trial registrationNCT02881099; Results.

Indexed as

HeterozygoteAgedAge of OnsetCognitive DysfunctionCohort StudiesDementiaFemaleGlucosylceramidaseHumansMaleMiddle AgedMutationParkinson DiseaseProspective StudiesUnited KingdomGlucosylceramidase

Identifiers

PMID29378790
PMCPMC6031283
OpenAlexW2787157191

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.